

ASX Announcement

Medibio Limited – 12 March 2019



Medibio Announces Entitlement Issue Results and Shortfall Notification

Melbourne, Australia and Minneapolis, MN – 12 March 2019: Medibio Limited (MEB or the Company) (ASX: MEB)(OTCQB: MDBIF) is pleased to advise that the non-renounceable entitlement issue (Entitlement Issue) announced by the Company on Monday, 10 December 2018 closed on Thursday, 7 March 2019 with applications for entitlements and shortfall shares. The Company received applications for 46,173,228 new fully paid ordinary shares amounting to total subscriptions of \$923,464.56.

Below is a table outlining the effects of the Entitlement Issue on the capital structure of the Company:

EVENT	NO. OF SHARES
Shares currently on issue	202,628,271
Maximum shares offered under the Entitlement Issue	202,628,271
Shares applied for under the Entitlement Issue	41,140,559
Additional shares applied for under the Entitlement Issue	5,032,669
Shortfall shares available after completion of Entitlement Issue	156,455,043

The Company intends to issue and allot all entitlement shares and shortfall shares applied for by shareholders in line with the Entitlement Issue timetable and intends to apply to ASX for quotation of all entitlement shares in accordance with the Offer document. The number of shares on issue in the Company after the issue of entitlement and shortfall shares will be 248,801,499.

The Company advises that there are 156,455,043 shortfall shares following the Entitlement Issue.

The Directors wish to thank all shareholders for their continued support.

If you wish to speak with the Company directly, please contact Melanie Leydin on +61 3 9692 7222.

Yours faithfully,

David Kaysen
Chairman, Managing Director and CEO

-END-